Answer
Yes, a retrospective cohort study suggested a possibly increased melanoma risk with rasagiline tartrate, especially with longer exposure and/or higher cumulative doses; new or changing skin lesions warrant medical review.
Sources for this answer
- Rasagiline Milpharm 1 mg tabletsAurobindo Pharma - Milpharm Ltd. · emc · SmPC §4.4 Special warnings and precautions for use · Version 4Document updated
Sources checked